Fulcrum Therapeutics reports bigger Q4 net loss

Reuters02-24
<a href="https://laohu8.com/S/FULC">Fulcrum Therapeutics</a> reports bigger Q4 net loss

Overview

  • Biopharmaceutical firm reported Q4 net loss of $20.3 mln

  • Company ended 2025 with $352.3 mln in cash, cash equivalents, and marketable securities

  • Announced positive 12-week results from Phase 1b PIONEER trial in sickle cell disease

Outlook

  • Fulcrum plans to initiate a registration-enabling trial for pociredir in H2 2026

  • Company expects cash runway to fund operations into 2029

  • Activating sites for open-label extension trial to evaluate pociredir's safety

Result Drivers

  • PIONEER TRIAL RESULTS - 20 mg dose cohort in Phase 1b PIONEER trial showed 12.2% increase in fetal hemoglobin, improvements in hemolysis and anemia markers

  • CASH POSITION - Ended 2025 with $352.3 mln in cash, cash equivalents, and marketable securities, providing runway into 2029

  • FUTURE TRIAL PLANS - Plans to initiate a potential registration-enabling trial in the second half of 2026, pending FDA feedback

Company press release: ID:nGNX1S9hHc

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Net Income

-$20.30 mln

Q4 Basic EPS

-$0.31

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Fulcrum Therapeutics Inc is $23.00, about 111.2% above its February 23 closing price of $10.89

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment